𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia

✍ Scribed by Letendre, Louis ;Hinemann, Vicky ;Hoagland, H. Clark ;Kovach, John S.

Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
291 KB
Volume
13
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Fourteen patients with refractory acute nonlymphocytic leukemia were entered into a doseseeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days. There were three complete responses lasting 2 months, 3 months, and 10 months and two transient partial remissions. Dose-limiting toxicities were stomatitis and diarrhea. Prolonged aplasia occurred at the highest doses tested and appeared to result from repetitive doses of the combination given as maintenance. We recommend for induction and consolidation/intensification treatment VP-16, 125 mg/m2, and AMSA, 125 mg/m2, intravenously daily for 5 days. A reduction by at least 50% in the dose of each drug is recommended for maintenance of complete remissions.

πŸ“œ SIMILAR VOLUMES

Treatment of refractory acute myeloid le
Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: Results of a clinical phase I/II study
✍ Wolfgang Hiddemann; Dieter Urbanitz; Peter Preusser; Wolf Achterrath; Thomas BΓΌc πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 482 KB

Twenty patients with refractory AML were treated with mAMSA and VP 16-2 13 in combination to assess the toxicity and anti-leukemic activity of the two-drug regimen. Refractoriness was defined according to the response to induction therapy consisting of 6-thioguanine, cytosine arabinoside and daunoru

VP 16–213 and cyclophosphamide in the tr
VP 16–213 and cyclophosphamide in the treatment of refractory acute nonlymphocytic leukemia with monocytic features
✍ Hurd, David D. ;Peterson, Bruce A. ;McKenna, Robert W. ;Bloomfield, Clara D. πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 281 KB

## Abstract The treatment of refractory acute nonlymphocytic leukemia remains a major clinical problem in leukemia therapy. VP 16–213 is an investigational agent that may have specificity for monocytic blasts, and the combination of VP 16–213 and cyclophosphamide is synergistic in experimental leuk

Phase I–II trial of VP-16 in the treatme
Phase I–II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia
✍ Mailliard, James A. ;Letendre, Louis ;Dalton, Robert J. ;Levitt, Ralph ;Gerstner πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 442 KB

VP-16 was used to treat newly diagnosed elderly ( 2 6 5 yr) patients with acute nonlymphocytic leukemia (ANLL) and patients with blast crisis of chronic granulocytic leukemia (BI-CGL). Our pilot study indicated that VP-I6 160 mg/m2 intravenously daily for 5 days was well tolerated and suggested a di